OSGIN2

Summary

OSGIN2 (oxidative stress induced growth inhibitor family member 2, HGNC:1355) is a protein-coding gene on chromosome 8q21.3, encoding Oxidative stress-induced growth inhibitor 2 (Q9Y236). Monooxygenase catalytic activity.

Predicted to enable growth factor activity. Predicted to be involved in negative regulation of cell growth.

Source: NCBI Gene 734 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_001126111

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1355
Approved symbol	OSGIN2
Name	oxidative stress induced growth inhibitor family member 2
Location	8q21.3
Locus type	gene with protein product
Status	Approved
Aliases	hT41
Ensembl gene	ENSG00000164823
Ensembl biotype	protein_coding
OMIM	604598
Entrez	734

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000297438, ENST00000451899, ENST00000520659, ENST00000647849, ENST00000869563

RefSeq mRNA: 2 — MANE Select: NM_001126111 NM_001126111, NM_004337

CCDS: CCDS47888, CCDS6248

Canonical transcript exons

ENST00000451899 — 6 exons

Exon	Start	End
ENSE00001087794	89914077	89914213
ENSE00001087795	89914555	89914746
ENSE00001087804	89921080	89921171
ENSE00002111228	89924503	89927888
ENSE00002310338	89902570	89902837
ENSE00003546734	89909567	89909721

Expression profiles

Bgee: expression breadth ubiquitous, 239 present calls, max score 96.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 38.5488 / max 567.6905, expressed in 1818 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
89683	33.7259	1818
89684	2.1525	1088
89682	1.2595	389
89681	1.1404	502
89685	0.1997	81
89680	0.0708	20

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	96.30	gold quality
decidua	UBERON:0002450	92.39	gold quality
male germ cell	CL:0000015	92.28	gold quality
islet of Langerhans	UBERON:0000006	87.79	gold quality
gall bladder	UBERON:0002110	87.49	gold quality
mucosa of stomach	UBERON:0001199	86.15	gold quality
tibial nerve	UBERON:0001323	86.09	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	85.98	gold quality
calcaneal tendon	UBERON:0003701	85.64	gold quality
monocyte	CL:0000576	85.62	gold quality
right lung	UBERON:0002167	85.48	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.46	gold quality
lower esophagus	UBERON:0013473	85.40	gold quality
leukocyte	CL:0000738	85.32	gold quality
mononuclear cell	CL:0000842	85.30	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.41	gold quality
hindlimb stylopod muscle	UBERON:0004252	84.29	gold quality
smooth muscle tissue	UBERON:0001135	84.28	gold quality
lower lobe of lung	UBERON:0008949	83.89	gold quality
adipose tissue	UBERON:0001013	83.75	gold quality
spinal cord	UBERON:0002240	83.68	gold quality
body of uterus	UBERON:0009853	83.58	gold quality
subcutaneous adipose tissue	UBERON:0002190	83.32	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	83.31	gold quality
muscle of leg	UBERON:0001383	82.95	gold quality
biceps brachii	UBERON:0001507	82.91	gold quality
connective tissue	UBERON:0002384	82.88	gold quality
adenohypophysis	UBERON:0002196	82.76	gold quality
gastrocnemius	UBERON:0001388	82.74	gold quality
popliteal artery	UBERON:0002250	82.66	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6142	no	91.93
E-ANND-3	no	4.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

114 targeting OSGIN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-450B-5P	99.92	71.48	3175

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	osgin2	ENSDARG00000040302
mus_musculus	Osgin2	ENSMUSG00000041153
rattus_norvegicus	Osgin2	ENSRNOG00000009358
caenorhabditis_elegans		WBGENE00017934

Paralogs (1): OSGIN1 (ENSG00000140961)

Protein

Protein identifiers

Oxidative stress-induced growth inhibitor 2 — Q9Y236 (reviewed: Q9Y236)

Alternative names: hT41

All UniProt accessions (2): E5RJZ3, Q9Y236

UniProt curated annotations — full annotation on UniProt →

Function. Monooxygenase catalytic activity. May be involved in meiosis or the maturation of germ cells.

Subcellular location. Midbody.

Tissue specificity. Ubiquitous. Expressed at higher levels in testis and ovary.

Cofactor. No monooxygenase catalytic activity in the absence of NADPH.

Similarity. Belongs to the OKL38 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y236-1	1	yes
Q9Y236-2	2

RefSeq proteins (2): NP_001119583, NP_004328 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029731	OSGIN1/2	Family
IPR036188	FAD/NAD-bd_sf	Homologous_superfamily

UniProt features (4 total): sequence variant 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y236-F1	87.81	0.70

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 184 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, FISCHER_G1_S_CELL_CYCLE, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GOBP_GROWTH, GOMF_GROWTH_FACTOR_ACTIVITY, MODULE_285, BLALOCK_ALZHEIMERS_DISEASE_UP, TGTGTGA_MIR377, ATTCTTT_MIR186, NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON, DOUGLAS_BMI1_TARGETS_UP, GOMF_SIGNALING_RECEPTOR_BINDING, GRADE_COLON_AND_RECTAL_CANCER_DN

GO Biological Process (3): negative regulation of cell growth (GO:0030308), meiotic cell cycle (GO:0051321), signal transduction (GO:0007165)

GO Molecular Function (3): monooxygenase activity (GO:0004497), growth factor activity (GO:0008083), oxidoreductase activity (GO:0016491)

GO Cellular Component (1): midbody (GO:0030496)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
cell cycle	1
sexual reproduction	1
reproductive process	1
meiotic nuclear division	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
oxidoreductase activity	1
receptor ligand activity	1
catalytic activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

955 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OSGIN2	DECR1	Q16698	896
OSGIN2	CALB1	P05937	833
OSGIN2	CA7	P43166	764
OSGIN2	CALB2	P22676	638
OSGIN2	FRMPD3	Q5JV73	456
OSGIN2	NBN	O60934	436
OSGIN2	GPR146	Q96CH1	388
OSGIN2	S100G	P29377	381
OSGIN2	PPM1H	Q9ULR3	368
OSGIN2	ZNF239	Q16600	348
OSGIN2	LIN52	Q52LA3	346
OSGIN2	STAC	Q99469	339
OSGIN2	MSL1	Q68DK7	330
OSGIN2	ZNF7	P17015	323
OSGIN2	HTD2	P86397	321

IntAct

1 interactions, top by confidence:

A	B	Type	Score
OSGIN2	H1-1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (7): OSGIN2 (Synthetic Lethality), OSGIN2 (Proximity Label-MS), OSGIN2 (Affinity Capture-MS), OSGIN2 (Proximity Label-MS), OSGIN2 (Proximity Label-MS), OSGIN2 (Proximity Label-MS), OSGIN2 (Affinity Capture-RNA)

ESM2 similar proteins: A0A0E3D8M4, A0A0L1JEZ9, A0A140JWS7, A0A1C8AX29, A0A2I2F2K8, A0A411PQP8, A1A653, A7XRY0, A8NF99, B2KWH9, B2KWI1, D2E9W9, D4AU57, D4B1Y1, E9QYP0, G5EB76, I1RN13, J4W6X9, M2PP75, N4WYI1, O13907, O95831, P0DXV5, P0DXV6, P11637, P34229, P82861, Q09694, Q19910, Q2TZB2, Q2U6D4, Q4IER0, Q4U3U3, Q4U3U5, Q4WF56, Q4WVD1, Q4WZB3, Q5AYI6, Q5BH52, Q75BV4

Diamond homologs: Q8VC10, Q9UJX0, Q9Y236

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	8
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

846 predictions. Top by Δscore:

Variant	Effect	Δscore
8:89909562:TAAA:T	acceptor_loss	1.0000
8:89909563:A:AG	acceptor_gain	1.0000
8:89909564:A:AG	acceptor_gain	1.0000
8:89909564:AAG:A	acceptor_loss	1.0000
8:89909565:A:AG	acceptor_gain	1.0000
8:89909565:A:AT	acceptor_loss	1.0000
8:89909566:G:GG	acceptor_gain	1.0000
8:89909566:GA:G	acceptor_gain	1.0000
8:89909566:GAA:G	acceptor_gain	1.0000
8:89909566:GAAAC:G	acceptor_gain	1.0000
8:89909717:AATAG:A	donor_gain	1.0000
8:89909718:ATAG:A	donor_gain	1.0000
8:89909719:TAG:T	donor_gain	1.0000
8:89909720:AG:A	donor_gain	1.0000
8:89909720:AGGTA:A	donor_loss	1.0000
8:89909721:GG:G	donor_gain	1.0000
8:89909721:GGT:G	donor_loss	1.0000
8:89909722:G:GG	donor_gain	1.0000
8:89909722:GT:G	donor_loss	1.0000
8:89921078:A:AG	acceptor_gain	1.0000
8:89921079:G:GG	acceptor_gain	1.0000
8:89921149:GAC:G	donor_gain	1.0000
8:89921156:TATC:T	donor_gain	1.0000
8:89921157:ATCA:A	donor_gain	1.0000
8:89924500:TAG:T	acceptor_loss	1.0000
8:89924501:A:AG	acceptor_gain	1.0000
8:89924501:A:T	acceptor_loss	1.0000
8:89924501:AG:A	acceptor_gain	1.0000
8:89924502:G:GC	acceptor_loss	1.0000
8:89924502:G:GG	acceptor_gain	1.0000

AlphaMissense

3582 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:89914741:T:A	W131R	0.999
8:89914741:T:C	W131R	0.999
8:89921107:A:C	S142R	0.999
8:89921109:C:A	S142R	0.999
8:89921109:C:G	S142R	0.999
8:89914625:T:C	L92P	0.998
8:89914675:T:A	W109R	0.998
8:89914675:T:C	W109R	0.998
8:89914712:T:A	V121D	0.998
8:89914743:G:C	W131C	0.998
8:89914743:G:T	W131C	0.998
8:89914619:A:T	D90V	0.997
8:89925401:G:C	G463R	0.997
8:89914104:C:T	S32F	0.996
8:89914128:C:A	P40Q	0.996
8:89914625:T:A	L92H	0.996
8:89914625:T:G	L92R	0.996
8:89921129:T:C	L149P	0.996
8:89924955:C:A	A314D	0.996
8:89924960:G:C	A316P	0.996
8:89925048:T:C	L345P	0.996
8:89925062:T:G	Y350D	0.996
8:89925426:T:A	V471D	0.996
8:89925431:T:C	F473L	0.996
8:89925433:T:A	F473L	0.996
8:89925433:T:G	F473L	0.996
8:89909721:G:A	G23R	0.995
8:89909721:G:C	G23R	0.995
8:89914077:G:A	G23E	0.995
8:89914077:G:T	G23V	0.995

dbSNP variants (sampled 300 via entrez): RS1000204755 (8:89926216 T>C), RS1000243361 (8:89926890 G>A), RS1000546438 (8:89927571 A>G), RS1000585839 (8:89908308 T>C), RS1000831051 (8:89902433 C>A,G), RS1001220501 (8:89915417 GCC>G), RS1001314449 (8:89922314 C>A,T), RS1001345462 (8:89921307 G>A), RS1001436588 (8:89921927 C>T), RS1001440271 (8:89920717 C>T), RS1001531135 (8:89901923 A>G,T), RS1001612880 (8:89902434 G>A), RS1001705098 (8:89915736 C>A,G,T), RS1001709751 (8:89907846 G>A,T), RS1002016942 (8:89927612 C>T)

Disease associations

OMIM: gene MIM:604598 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006627_78	Diastolic blood pressure	4.000000e-09
GCST010266_7	Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass	3.000000e-09
GCST010267_1	Trunk fat mass adjusted for trunk lean mass	2.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0007785	femoral neck bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	4
Cyclosporine	increases expression, decreases expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Cadmium Chloride	increases abundance, increases expression	2
Particulate Matter	increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
sulforaphane	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
cupric chloride	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression	1
polyhexamethyleneguanidine	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
MT19c compound	increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Vehicle Emissions	increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.